Pharmacokinetics and immunologic consequences of exposing macaques to purified homologous butyrylcholinesterase

Life Sciences

Volumn 72, Issue 2, 2002, Pages 125-134

  Rosenberg, Yvonne ^a   Luo, Chunyuan ^b   Ashani, Yacov ^c   Doctor, Bhupendra P ^b   Fischer, Randy ^d   Wolfe, Gary ^d   Saxena, Ashima ^b  

^a ProCell Corporation   (United States)

^b WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^c ISRAEL INSTITUTE FOR BIOLOGICAL RESEARCH   (Israel)

^d TherImmune Research Corporation   (United States)

Author keywords

Bioscavenger; Cholinesterases; Immunological consequences; Organophosphate poisoning; Pharmacokinetics

Indexed keywords

CARBOHYDRATE; CHOLINESTERASE; ENZYME ANTIBODY; ORGANOPHOSPHORUS COMPOUND; PESTICIDE;

ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ARTICLE; CARBOHYDRATE ANALYSIS; CONTROLLED STUDY; DRUG DETOXIFICATION; ENZYME ACTIVITY; IMMUNE RESPONSE; MACACA; NONHUMAN; RABBIT; RHESUS MONKEY;

ANIMALS; BUTYRYLCHOLINESTERASE; ENZYME-LINKED IMMUNOSORBENT ASSAY; HORSES; HUMANS; IMMUNOGLOBULIN G; MACACA MULATTA; ORGANOPHOSPHORUS COMPOUNDS; SPECTROPHOTOMETRY, ULTRAVIOLET;

EQUIDAE; MACACA; MACACA MULATTA; ORYCTOLAGUS CUNICULUS;

EID: 0037195578     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0024-3205(02)02203-8     Document Type: Article

References (35)

1. Doctor B.P., Maxwell D.M., Ashani Y., Saxena A., Gordon R.K. New approaches to Medical protection against chemical warfare nerve agents. Somani S.M., Romano J.A. Jr. Chemical Warfare Agents: Toxicity at low levels. 2001;191-214 CRC Press, New York.
2. Wolfe A.D., Rush R.S., Doctor B.P., Koplovitz I., Jones D. Acetylcholinesterase prophylaxis against organophosphate toxicity. Fundamental Applied Toxicology. 9:1987;266-270.
3. Brandeis R., Raveh L., Grunwald J., Cohen E., Ashani Y. Prevention of soman-induced cognitive deficits by pretreatment with human butyrylcholinesterase in rats. Pharmacology, Biochemistry and Behaviour. 46:1993;889-896.
4. Maxwell D.M., Castro C.A., De La Hoz D.M., Gentry M.K., Gold M.B., Solana R.P., Wolfe A.D., Doctor B.P. Protection of rhesus monkeys against soman and prevention of performance decrement by pretreatment with acetylcholinesterase. Toxicology and Applied Pharmacology. 115:1992;44-49.
5. Raveh L., Ashani Y., Levy D., De La Hoz D., Wolfe A.D., Doctor B.P. Acetylcholinesterase prophylaxis against organophosphate poisoning. Quantitative correlation between protection and blood-enzyme level in mice. Biochemical Pharmacology. 41:1991;37-41.
6. Raveh L., Grunwald J., Marcus D., Papier Y., Cohen E., Ashani Y. Human butyrylcholinesterase as a general prophylactic antidote for nerve agent toxicity. In vitro and in vivo quantitative characterization. Biochemical Pharmacology. 45:1993;2465-2474.
7. Raveh L., Grauer E., Grunwald J., Cohen E., Ashani Y. The stoichiometry of protection against soman and VX toxicity in monkeys pretreated with human butyrylcholinesterase. Toxicology and Pharmacology. 145:1997;43-53.
8. Allon N., Raveh L., Gilat E., Cohen E., Grunwald J., Ashani Y. Prophylaxis against soman inhalation toxicity in guinea pigs by pretreatment alone with human serum butyrylcholinesterase. Toxicological Sciences. 43:1998;121-128.
9. Saxena A., Raveh L., Ashani Y., Doctor B.P. Structure of glycan moieties responsible for the extended circulatory life time of fetal bovine serum acetylcholinesterase and equine serum butyrylcholinesterase. Biochemistry. 36:1997;7481-7489.
10. Saxena A., Ashani Y., Raveh L., Stevenson D., Patel T., Doctor B.P. Role of oligosaccharides in the pharmacokinetics of tissue-derived and genetically engineered cholinesterases. Molecular Pharmacology. 53:1998;112-122.
11. Castro C.A., Gresham V.C., Finger A.V., Maxwell D.M., Solana R.P., Lenz D.E., Broomfield C.A. Behavioral decrements persist in rhesus monkeys trained on a serial probe recognition task despite protection against soman lethality by butyrylcholinesterase. Neurotoxicology Teratology. 16:1994;145-148.
12. Cascio C., Comite C., Ghira M., Lanza G., Ponchione A. The use of serum cholinesterase in severe phosphorus poisoning. Personal experience. Minerva Anestesiology. 54:1988;337-338.
13. Genovese R.F., Lu X.-C., Gentry M.K., Larrison R., Doctor B.P. Evaluation of purified horse serum butyrylcholinesterase in rats. Proceedings of the Medical Defense Bioscience Review. 31:1993;1035-1042.
14. Ashani Y. Prospective of human butyrylcholinesterase as a detoxifying antidote and potential regulator of controlled-release drugs. Drug Development Research. 50:2000;298-308.
15. Hoffman R.S., Morasco R., Goldfrank L.R. Administration of purified human plasma cholinesterase protects against cocaine toxicity in mice. Journal of Toxicology and Clinical Toxicology. 34:1996;259-266.
16. Lynch T.J., Mattes C.E., Singh A., Bradley R.M., Brady R.O., Dretchen K.L. Cocaine detoxification by human plasma. Toxicology and Applied Pharmacology. 145:1997;363-371.
17. Mattes C.E., Lynch T.J., Singh A., Bradley R.M., Kellaris P.A., Brady R.O., Dretchen K.L. Therapeutic use of butyrylcholinesterase for cocaine intoxication. Toxicology and Applied Pharmacology. 145:1997;372-380.
18. Lockridge O. Genetic variants of human serum cholinesterase influence metabolism of the muscle relaxant succinylcholine. Pharmacology Therapy. 47:1990;35-60.
19. Jenkins T., Balinsky D., Patient D.W. Cholinesterase in plasma: First reported absence in the Bantu: Half-life determination. Science. 156:1967;1748-1749.
20. Stovner J., Stadskleiv K. Suxamethonium apnea terminated with commercial serum cholinesterase. Acta Anaesthesiologica Scandinavica. 20:1976;211-215.
21. Ostergaard D., Viby-Mogensen J., Hanel H.K., Skovgaard L.T. Half-life of plasma cholinesterase. Acta Anaesthesiologica Scandinavica. 32:1988;266-269.
22. Ohkura T., Hada T., Higashino K., Ohue T., Kochibe N., Yamashita K. Increase of fucosylated serum cholinesterase in relation to high risk groups for hepatocellular carcinomas. Cancer Research. 54:1994;55-61.
23. Kronman C., Chitlaru T., Elhanany E., Velan B., Shafferman A. Hierchy of post-translational modifications involved in the circulatory longevity of glycoproteins. Journal of Biological Chemistry. 275:2000;29488-29502.
24. Lehrman M.A., Pizzo S.V., Imber M.J., Hill R.L. The binding of fucose-containing glycoproteins by hepatic lectins. Journal of Biological Chemistry. 261:1986;7412-7418.
25. Ashwell G., Harford J. Carbohydrate -specific receptors of the liver. Annual Reviews in Biochemistry. 51:1982;531-554.
26. Ashwell G., Morell A.G. The role of surface carbohydrates in the hepatic recognition and transport of circulating glycoproteins. Advances in Enzymology. 41:1974;99-128.
27. Day J.F., Thornburg R.W., Thorpe S.R., Baynes J.W. Carbohydrate-mediated clearance of antibody antigen complexes from the circulation. Journal of Biological Chemistry. 255:1980;2360-2365.
28. Gentry M.K., Nuwayser E.S., Doctor B.P. Effects of repeated administration of butyrylcholinresterase on antibody induction in rabbits. Proceedings of the Medical Defense Bioscience Review. 3:1993;1051-1056.
29. Gentry M.K., Nuwayser E.S., Doctor B.P. Immunological effect of repeated administration of cholinesterases in rabbits. Proceedings of the Medical Defense Bioscience Review. 1:1996;183-191.
30. Matzke S.M., Oubre J.L., Caranto G.R., Gentry M.K., Galbicka G. Behavioral and immunological effects of exogenous butyrylcholinesterase in rhesus monkeys. Pharmacology, Biochemistry and Behaviour. 62:1999;523-530.
31. De La Hoz D., Doctor B.P., Ralston J.S., Rush R.S., Wolfe A.D. A simplified procedure for the purification of large quantities of mammalian acetylcholinesterase. Life Sciences. 39:1986;195-199.
32. Grunwald J., Marcus D., Papier Y., Raveh L., Pittel Z., Ashani Y. A large scale purification and long-term stability of human butyrylcholinesterase: a potential bioscavenger drug. Journal of Biochemical and Biophysical Methods. 34:1997;123-135.
33. Laub P.B., Gallo J.M. N-COMP- A windows-based program for noncompartmental analysis of pharmacokinetic data. Journal of Pharmacological Science. 85:1996;393-395.
34. Ellman G.L., Courtney K.D., Andres V., Featherstone R.M. A new and rapid colorimetric determination of acetlycholinesterase activity. Biochemical Pharmacology. 7:1961;88-95.
35. Ashani Y., Grauer E., Grunwald J., Allon N., Raveh L. Current capabilities in extrapolating from animal to human the capacity of human butyrylcholinesterase to detoxify organophosphates. Doctor B.P., Taylor P., Quinn D.M., Rotundo R.L., Gentry M.K. Structure and Function of Cholinesterases and Related Proteins. 1998;255-260 Plenum Press, New York.